These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 35616365)

  • 41. Association between clinicopathologic characteristics and BRAF
    Huang H; Lu T; Sun Y; Li S; Li J; Xu K; Feng RE; Xu ZJ
    Thorac Cancer; 2019 Oct; 10(10):1984-1992. PubMed ID: 31441596
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Neurodegeneration in patients with multisystem Langerhans cell histiocytosis treated with vemurafenib.
    Trambusti I; Pegoraro F; Gaspari S; Dell'Acqua F; Cellini M; Trizzino A; Tondo A; Perrone A; Coniglio ML; Guerrini R; Barba C; Sieni E
    Br J Haematol; 2024 Jun; 204(6):2508-2511. PubMed ID: 38665038
    [No Abstract]   [Full Text] [Related]  

  • 43. Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.
    Diamond EL; Durham BH; Haroche J; Yao Z; Ma J; Parikh SA; Wang Z; Choi J; Kim E; Cohen-Aubart F; Lee SC; Gao Y; Micol JB; Campbell P; Walsh MP; Sylvester B; Dolgalev I; Aminova O; Heguy A; Zappile P; Nakitandwe J; Ganzel C; Dalton JD; Ellison DW; Estrada-Veras J; Lacouture M; Gahl WA; Stephens PJ; Miller VA; Ross JS; Ali SM; Briggs SR; Fasan O; Block J; Héritier S; Donadieu J; Solit DB; Hyman DM; Baselga J; Janku F; Taylor BS; Park CY; Amoura Z; Dogan A; Emile JF; Rosen N; Gruber TA; Abdel-Wahab O
    Cancer Discov; 2016 Feb; 6(2):154-65. PubMed ID: 26566875
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease.
    Haroche J; Cohen-Aubart F; Emile JF; Maksud P; Drier A; Tolédano D; Barete S; Charlotte F; Cluzel P; Donadieu J; Benameur N; Grenier PA; Besnard S; Ory JP; Lifermann F; Idbaih A; Granel B; Graffin B; Hervier B; Arnaud L; Amoura Z
    J Clin Oncol; 2015 Feb; 33(5):411-8. PubMed ID: 25422482
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment of multisystem Langerhans cell histiocytosis. Results of the DAL-HX 83 and DAL-HX 90 studies. DAL-HX Study Group.
    Minkov M; Grois N; Heitger A; Pötschger U; Westermeier T; Gadner H
    Klin Padiatr; 2000; 212(4):139-44. PubMed ID: 10994540
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Langerhans cell histiocytosis is a neoplasm and consequently its recurrence is a relapse: In memory of Bob Arceci.
    Egeler RM; Katewa S; Leenen PJ; Beverley P; Collin M; Ginhoux F; Arceci RJ; Rollins BJ;
    Pediatr Blood Cancer; 2016 Oct; 63(10):1704-12. PubMed ID: 27314817
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Cladribine for 13 cases refractory high-risk children Langerhans cell histiocytosis].
    Hu T; Liu R; Li J; Cao J; Zhang L; Li J; Fan W; Zhong D; Shi X
    Zhonghua Xue Ye Xue Za Zhi; 2014 Nov; 35(11):985-9. PubMed ID: 25417874
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Recurrent and Refractory Langerhans Cell Histiocytosis in Children Treated with the Combination of Cladribine and Cytarabine].
    DU Y; Xiong H; Li H; Li JX; Tao F; Yang L; Lu WJ; Qi SS; Zhang LN
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Jun; 30(3):943-949. PubMed ID: 35680831
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-term outcomes in patients with relapsed or refractory hairy cell leukemia treated with vemurafenib monotherapy.
    Handa S; Lee JO; Derkach A; Stone RM; Saven A; Altman JK; Grever MR; Rai KR; Shukla M; Vemuri S; Montoya S; Taylor J; Abdel-Wahab O; Tallman MS; Park JH
    Blood; 2022 Dec; 140(25):2663-2671. PubMed ID: 35930750
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Genetic landscape of adult Langerhans cell histiocytosis with lung involvement.
    Jouenne F; Chevret S; Bugnet E; Clappier E; Lorillon G; Meignin V; Sadoux A; Cohen S; Haziot A; How-Kit A; Kannengiesser C; Lebbé C; Gossot D; Mourah S; Tazi A
    Eur Respir J; 2020 Feb; 55(2):. PubMed ID: 31806714
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Pathophysiology and treatment of adult Langerhans cell histiocytosis].
    Tojo A; Kobayashi M
    Rinsho Ketsueki; 2020; 61(9):1028-1034. PubMed ID: 33162496
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Langerhans Cell Histiocytosis Associated With Renal Cell Carcinoma Is a Neoplastic Process: Clinicopathologic and Molecular Study of 7 Cases.
    Agaimy A; Bonert M; Naqvi A; Wang C; Trpkov K; Dettmar P; Wintzer HO; Stoehr R; Hes O; Williamson SR; Gibson IW; Hartmann A
    Am J Surg Pathol; 2020 Dec; 44(12):1658-1665. PubMed ID: 32910018
    [TBL] [Abstract][Full Text] [Related]  

  • 53. From mutation to management: Advancing Langerhans cell histiocytosis treatment through combination therapies.
    Diamond A
    Br J Haematol; 2024 May; 204(5):1588-1589. PubMed ID: 38606542
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Intensification of induction therapy and prolongation of maintenance therapy did not improve the outcome of pediatric Langerhans cell histiocytosis with single-system multifocal bone lesions: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study.
    Morimoto A; Shioda Y; Imamura T; Kudo K; Kitoh T; Kawaguchi H; Goto H; Kosaka Y; Tsunematsu Y; Imashuku S;
    Int J Hematol; 2018 Aug; 108(2):192-198. PubMed ID: 29594922
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Somatic activating ARAF mutations in Langerhans cell histiocytosis.
    Nelson DS; Quispel W; Badalian-Very G; van Halteren AG; van den Bos C; Bovée JV; Tian SY; Van Hummelen P; Ducar M; MacConaill LE; Egeler RM; Rollins BJ
    Blood; 2014 May; 123(20):3152-5. PubMed ID: 24652991
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment of congenital Langerhans cell histiocytosis with cobimetinib.
    Benjelloun G; Roquet-Gravy C; Marot L; Secco LP; Roquet-Gravy PP; Baeck M; Bulinckx A
    Pediatr Dermatol; 2024; 41(3):515-517. PubMed ID: 38387093
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Characteristics and Treatment Outcomes of Pediatric Langerhans Cell Histiocytosis with Thymic Involvement.
    Yao JF; Wang D; Ma HH; Lian HY; Zhang L; Wang TY; Li ZG; Jiang J; Cui L; Zhang R
    J Pediatr; 2022 May; 244():194-202.e5. PubMed ID: 35065150
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effectiveness and Safety of Dabrafenib in the Treatment of 20 Chinese Children with BRAFV600E-Mutated Langerhans Cell Histiocytosis.
    Yang Y; Wang D; Cui L; Ma HH; Zhang L; Lian HY; Zhang Q; Zhao XX; Zhang LP; Zhao YZ; Li N; Wang TY; Li ZG; Zhang R
    Cancer Res Treat; 2021 Jan; 53(1):261-269. PubMed ID: 32972045
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pediatric Langerhans Cell Histiocytosis with BRAF Mutation Affecting Sacral Vertebra: A Case Report and Disease Review.
    Champaneri H; Banerjee AD
    Pediatr Neurosurg; 2020; 55(3):169-174. PubMed ID: 32739910
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Treatment of children with multiple system Langerhans cell histiocytosis by Japan Langerhans Cell Histiocytosis Study Group Protocol].
    Huang JB; Xue HM; Chen YY; Huang K
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Feb; 21(1):146-9. PubMed ID: 23484709
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.